Biotechnology equities like Voyager Therapeutics experience downward stock price pressure due to standard sector-wide factors, including clinical trial delays, broader market rotations away from pre-revenue growth stocks, or dilution from secondary equity offerings used to fund ongoing research. Because clinical-stage enterprises rely heavily on positive experimental readouts and milestone achievements, any negative clinical data, regulatory hurdles, or conservative corporate financial guidance can trigger short-term sell-offs among investors.